CTRI/2017/10/010021
Recruiting
Phase 3
Efficacy and safety of intralesional injection of mumps-measles-rubella (MMR) vaccine in the treatment of multiple cutaneous warts: a clinical trial
Dr Prof Shyam Sundar Chaudhary0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Multiple Cutaneous Warts
- Sponsor
- Dr Prof Shyam Sundar Chaudhary
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •i.Male or female patients with multiple warts who are candidate for treatment between 18 and 65 years of age (both inclusive).
- •ii.Patients who give their informed consent.
Exclusion Criteria
- •i.Pregnant and lactating women.
- •ii.Any evidence of immunosuppression (eg. HIV infection, organ transplantation, long term steroid use etc.).
- •iii.Any other systemic disease (eg. liver or kidney disorder).
- •iv.Presence of mucosal wart(s).
- •v.Presence of ulcerated or inflamed wart(s).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Study with hzVSF-v13 in patients with COVID-19 pneumonia: a phase II, proof of concept, multicentre, randomized, parallel-group, double-blind, placebo-controlled studyModerate-to-severe COVID-19 pneumoniaMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2020-003614-13-ITImmuneMed Inc.105
Not yet recruiting
Phase 3
role of injectable platelet rich fibrin in periodontal diseasesCTRI/2023/09/057296TEPARAMESWARI
Not yet recruiting
Phase 2
Efficacy of prophylactic adminstration of diphenhydramine and dexmedetomidine during anesthesia on emergence agitation and quality of recovery after Orthognathic surgeries.IRCT20130304012695N19Tehran University of Medical Sciences80
Completed
Not Applicable
Assessment on safety of intravenously administered trastuzumab with 100 ml saline solution in HER2 positive breast cancerBreast cancerJPRN-UMIN000006710Shiga University of Medical Science30
Completed
Phase 2
Evaluating the effects of intravenous immunoglobulin (IVIG) in COVID-19 patientsIRCT20151227025726N20Shahid Beheshti University of Medical Sciences80